Kala Pharmaceuticals price target lowered to $15 from $18 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Kala Pharmaceuticals to $15 from $18 and keeps a Buy rating on the shares following the Q2 report.